Unveiling the origin and functions of diagnostic circulating microRNAs in lung cancer
- PMID: 40185877
- PMCID: PMC12081734
- DOI: 10.1038/s41416-025-02982-x
Unveiling the origin and functions of diagnostic circulating microRNAs in lung cancer
Abstract
Background: Circulating microRNAs (c-miRs) were shown to be effective biomarkers for lung cancer early detection. However, the understanding of c-miRs origin and their biological functions still remains elusive.
Methods: We analysed miRNA expression in a large panel of lung cancer (LC) and hematopoietic cell lines (N = 252; CCLE database) coupled with c-miR profile of a large cohort of serum samples (N = 975), from high-risk subjects underwent annual LD-CT for 5 years. Furthermore, we examined intracellular and extracellular miR-29a-3p/223-3p expression profile in lung adenocarcinoma (LUAD) tissues, in matched serum samples and in LC and stromal cell lines. Lastly, through the modulation of expression of selected c-miRs by using mimic (OE) or antisense microRNA (KD), we explored their impact on lung cancer transcriptome and cancer and immune phenotypes.
Results: Here, we investigated the origin of an extensively validated 13 c-miRs signature diagnostics for asymptomatic lung cancer (LC) in high-risk subjects (smokers, >20 packs/y; >50 y old). Overall, we found a mixed origin of these c-miRs, originating both from tumour cells and the tumour microenvironment (TME). Intriguingly, we revealed that circulating miR-29a-3p and miR-223-3p are abundantly released from LC epithelial cells and immune cells, respectively. In particular, we found that miR-223-3p triggered several lung cancer related phenotypes such as invasion, migration and tumour-promoting inflammation.
Conclusions: Our study highlights a mixed tumour epithelial and stroma-associated origin of LC c-miRs with new evidences on the multifaceted role of miR-223-3p in LC pathogenesis and immune modulation.
© 2025. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
Competing interests: The study funders had no role in the design of the study, the collection, analysis and interpretation of the data, the writing of the manuscript and the decision to submit the manuscript for publication. All the authors declare no conflict of interest. Ethics approval and consent to participate: Study was approved by internal IRB at IRCCS Casa Sollievo della Sofferenza Hospital (protocol name: BIOPOLMONE v1.0_08 Giu 16). Patients signed an informed consent in accordance with the Helsinki’s declaration.
References
MeSH terms
Substances
Grants and funding
- GR-2016-02363975/Ministero della Salute (Ministry of Health, Italy)
- RF-2021-12372433/Ministero della Salute (Ministry of Health, Italy)
- GR-2019-12370460/Ministero della Salute (Ministry of Health, Italy)
- IG 2024 - ID.30689/Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
LinkOut - more resources
Full Text Sources
Medical
Research Materials